Literature DB >> 15073765

Misclassification and selection bias in case-control studies using an automated database.

J M Evans1, T M MacDonald.   

Abstract

Automated databases are increasingly being used for pharmacoepidemiological research and fieldwork is often carried out to supplement and validate information held within them. In MEMO's case-control studies, patients are identified using computerized ICD9 diagnosis codes, the original medical records are retrieved and checked, and only patients fulfilling case inclusion criteria are used. The 20-30% of patients for whom medical records cannot be found are usually excluded. The aim is to eliminate misclassification bias. However, selection bias may be introduced if availability of medical records is associated with exposure. This investigation was therefore carried out to assess the relative importance of misclassification and selection bias. Data from four previous case-control studies, investigating the associations between NSAIDs and hospitalization for colitis, acute renal failure, appendicitis and colorectal cancer, were used. To assess misclassification, odds ratios (with 95% CI) for recent exposure to NSAIDs were compared in repeated studies that used all patients identified by ICD9 codes, with studies using validated cases only. Selection bias was assessed by comparing results in studies using patients for whom records could and could not be found. Results were plotted and the graphs indicated that misclassification bias was relatively unimportant, but that selection bias could be introduced into a study in this way. Copyright 1997 John Wiley & Sons, Ltd.

Entities:  

Year:  1997        PMID: 15073765     DOI: 10.1002/(SICI)1099-1557(199709/10)6:5<313::AID-PDS292>3.0.CO;2-K

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  9 in total

1.  Alternative outcome definitions and their effect on the performance of methods for observational outcome studies.

Authors:  Christian G Reich; Patrick B Ryan; Martijn J Schuemie
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

2.  Propensity-matched Analysis of Outcomes and Hospital Charges for Anterior Versus Posterior Cervical Fusion for Cervical Spondylotic Myelopathy.

Authors:  Joseph E Tanenbaum; Daniel Lubelski; Benjamin P Rosenbaum; Edward C Benzel; Thomas E Mroz
Journal:  Clin Spine Surg       Date:  2017-11       Impact factor: 1.876

3.  Validation of the diagnosis of venous thromboembolism in general practice database studies.

Authors:  R Lawrenson; J C Todd; G M Leydon; T J Williams; R D Farmer
Journal:  Br J Clin Pharmacol       Date:  2000-06       Impact factor: 4.335

4.  National Incidence of Patient Safety Indicators in the Total Hip Arthroplasty Population.

Authors:  Joseph E Tanenbaum; Derrick M Knapik; Glenn D Wera; Steven J Fitzgerald
Journal:  J Arthroplasty       Date:  2017-04-12       Impact factor: 4.757

5.  Disparities in reportable quality metrics by insurance status in the primary spine neoplasm population.

Authors:  Syed K Mehdi; Joseph E Tanenbaum; Vincent J Alentado; Jacob A Miller; Daniel Lubelski; Edward C Benzel; Thomas E Mroz
Journal:  Spine J       Date:  2016-09-21       Impact factor: 4.166

6.  Insurance status and reportable quality metrics in the cervical spine fusion population.

Authors:  Joseph E Tanenbaum; Jacob A Miller; Vincent J Alentado; Daniel Lubelski; Benjamin P Rosenbaum; Edward C Benzel; Thomas E Mroz
Journal:  Spine J       Date:  2016-08-04       Impact factor: 4.166

Review 7.  Pharmacoepidemiologic research in Australia: challenges and opportunities for monitoring patients with rheumatic diseases.

Authors:  Christine Y Lu
Journal:  Clin Rheumatol       Date:  2009-02-04       Impact factor: 2.980

8.  Lipid lowering drugs prescription and the risk of peripheral neuropathy: an exploratory case-control study using automated databases.

Authors:  Giovanni Corrao; Antonella Zambon; Lorenza Bertù; Edoardo Botteri; Olivia Leoni; Paolo Contiero
Journal:  J Epidemiol Community Health       Date:  2004-12       Impact factor: 3.710

9.  The Impact of Diagnostic Code Misclassification on Optimizing the Experimental Design of Genetic Association Studies.

Authors:  Steven J Schrodi
Journal:  J Healthc Eng       Date:  2017-10-18       Impact factor: 2.682

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.